Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment

Who can take part

• Patients aged ≥ 40 years
• Osteoarthritis of the hand according to American College of Rheumatology criteria 1990
• Osteoarthritis affecting at least two proximal and/or distal interphalangeal joints with a radiological Kellgren-Lawrence stage ≥ 2
• Symptomatic osteoarthritis within the last 3 months
• Visual analogue pain scale of the hand to be treated ≥ 40/100 mm (most painful hand)
• Inadequate response, adverse effects and/or contraindication to NSAIDs and non-opioid analgesics
• Patient affiliated to french social security or a similar health assurance

Who cannot take part

• Previous thrombosis/dissection of the radial artery
• History of allergy to iodinated contrast media, LipiodolⓇ or poppies
• Vasomotor disorders (Raynaud\'s syndrome, scleroderma, acrocyanosis)
• Obliterative arterial disease of the lower limbs at the critical ischaemia stage
• Severe to end-stage chronic renal insufficiency (glomerular filtration rate \< 30ml/min/1.73m2), dialysis or renal transplant
• Arteritis such as thromboangiitis obliterans disease or other diseases
• Chronic inflammatory rheumatic disease (rheumatoid arthritis, psoriatic arthritis, microcrystalline arthritis, etc.)
• Traumatic lesions, haemorrhages or chronic bleeding in the hand (not completely resolved within 3 months of the start of the lesion) requiring embolisation
• Stenosis (\>50%) or known atheromatous arterial occlusion of the upper limbs
• Known hyperthyroidism or large multinodular goiter
• Pregnant or breast-feeding
• Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code and/or who do not speak French
• Patients in a period of exclusion or in the course of another interventional clinical trial